Pfizer Will Pay $50 Million To Resolve Antitrust Claims Involving EpiPen
KANSAS CITY, Kan. — Pfizer Inc. has agreed to pay $50 million to settle claims that it conspired with others in an attempt to delay entry of generic competitors for the...To view the full article, register now.
Already a subscriber? Click here to view full article